Advertisement

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement

Apr

23

Today In Oncology

Claim Denials for Medicare Cancer-Related NGS Testing Show Uncertainty of Coverage

Radiotherapy Dosing for Head and Neck Squamous Cell Carcinoma

Extended Follow-up of Belzutifan Treatment for von Hippel-Lindau Disease-Associated RCC

MRD and Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC

Role of Pathologists in Improving Access to Safer More Effective Allogeneic Cell Therapies

Advertisement

© 2025 HSP News Service, L.L.C.